Evaluation of adherence to international guidelines for treating patients with type 2 diabetes mellitus in Kuwait by Al-Taweel, Dalal et al.
Strathprints Institutional Repository
Al-Taweel, Dalal and Awad, Abdelmoneim I and Johnson, Julienne (2012) Evaluation of adherence
to international guidelines for treating patients with type 2 diabetes mellitus in Kuwait. International
Journal of Clinical Pharmacy. ISSN 2210-7711
Strathprints is designed to allow users to access the research output of the University of Strathclyde.
Copyright c© and Moral Rights for the papers on this site are retained by the individual authors
and/or other copyright owners. You may not engage in further distribution of the material for any
profitmaking activities or any commercial gain. You may freely distribute both the url (http://
strathprints.strath.ac.uk/) and the content of this paper for research or study, educational, or
not-for-profit purposes without prior permission or charge.




Evaluation of adherence to international guidelines for treating
patients with type 2 diabetes mellitus in Kuwait
Dalal M. Al-Taweel • Abdelmoneim I. Awad •
B. Julienne Johnson
Received: 27 July 2012 / Accepted: 11 December 2012
 Springer Science+Business Media Dordrecht 2012
Abstract Background Clinical guidelines derived from
scientific evidence provide the basis of consistent stan-
dardized prescribing. Despite an alarming increase of dia-
betes in Kuwait, no studies related to the quality of
prescribing in diabetes were found. Before pharmaceutical
care can be implemented to improve the quality of care of
patients with diabetes, it is important to determine whether
prescribers are compliant with comprehensive international
guidelines for cardioprevention and glycaemic control.
Objective To evaluate the adherence to clinical guidelines
for treating patients with type 2 diabetes mellitus in primary
care centres and secondary care centres (hospitals) using a
developed and validated medication assessment tool with
reference to international guidelines. Setting Outpatient
diabetes clinics in 8 primary care centres and 4 secondary
care centres across four healthcare regions in Kuwait.
Method A quantitative, cross-sectional study involving a
sample of 652 Kuwaiti patients with type 2 diabetes, who
were selected using systematic sampling from the study
settings. Data were collected retrospectively from the
patients’ medical records using a validated 43-criterion
medication assessment tool (MATKW) designed to assess
cardioprevention and treatment in patients with type 2 dia-
betes. Descriptive and comparative analysis was conducted
using SPSS version 17. Main Outcome Measure Frequency
of prescribing adherence to agreed definitions of criteria
derived from international guidelines. Results Overall
adherence to prescribing diabetes guidelines was 77.7 %
(95 % CI 76.7–78.6 %). Significantly higher prescribing
adherence was found in the secondary care facilities, 82.4 %
(95 % CI 81.2–83.6 %) compared to primary care 72.5 %
(95 % CI 71.0–73.9 %) (p \ 0.001). Nineteen criteria out of
43 achieved an adherence [80 % in secondary care com-
pared to ten criteria in primary care. The documentation of
patients’ records was found to be inconsistent at the study
healthcare facilities. Nonoptimal achievement of target goals
for HbA1c, blood pressure and BMI was prevalent among the
study population. Conclusion: A tool such as MATKW
highlights areas for review and possible improvement in
prescribing adherence. Our findings reveal problem areas in
prescribing practices and documentation of patients’ records.
Cost-effective multifaceted interventions are needed to
improve current prescribing practices and documentation.
Keywords Clinical guidelines  Kuwait  Pharmaceutical
care  Prescribing  Type 2 diabetes
Impact on practice
• MATKW is a useful tool for quantifying guidelines
adherence and might serve as a valuable outcome
measure in routine practice as part of clinical audits and
identification of specific care issues that need to be
addressed in the absence of locally generated
guidelines.
• MATKW can be used to document and identify non-
adherences to guidelines and prompt pharmacists to
identify target patients who might best benefit from
extended pharmaceutical services.
• Criteria with low adherence identified by MATKW can
be potential areas for pharmacists to become involved
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in the care of patients with diabetes, especially in the
absence of locally generated guidelines.
Introduction
Diabetes is a chronic illness that is considered as one of the
most challenging health problems in the 21st century. In
2011, the number of people worldwide living with diabetes
was 336 million people, but it is expected to increase to
552 million by 2030 [1]. The prevalence of diabetes in
Kuwait has doubled in the last 15 years, reaching 21.2 %
in 2011 [1].
Diabetes results in chronic complications including
microvascular and macrovascular disorders. Evidence has
also shown that cardiovascular disease is the major cause
of morbidity and mortality for patients with diabetes and
has significant contribution to the direct and indirect costs
of diabetes [2]. Diabetes and its complications affect the
society’s economic status and have a great impact on
individuals, families, healthcare systems and countries, not
only due to cost of treatment, but also social costs and loss
of working days [3, 4].
The measurement of the quality of healthcare has been
identified as a priority in many health policy agendas
worldwide [5]. The need for change in diabetes manage-
ment and the standardisation of care by healthcare pro-
fessionals to offer consistent provision of best quality care
is repeatedly expressed. However, in order to plan and
implement changes to healthcare, there is a need to mea-
sure and assess current practice. Healthcare systems need
to develop a quality measurement framework at every level
to allow the improvement of patient care. A previous audit
in Kuwait measured the quality of diabetes care in primary
care settings by reviewing the administrative structure at
the selected clinics, as well as personnel and access to
specialized and laboratory services involved in diabetes
care [6]. However, no current published studies have been
conducted in Kuwait to evaluate prescribing practices for
patients with diabetes.
The goal of evidence-based clinical practice has led to
an increased interest in the development of tools to mea-
sure prescribing adherence to national guidelines. This aids
in detecting and measuring inappropriate prescribing to
specific patient groups by using quality standards extracted
from evidence-based guidelines. Medication assessment
tools (MATs), based on standards recommended by UK
clinical guidelines have been used in previous research to
quantify the level of adherence of prescribers to clinical
guidelines for different disease states including cancer and
diabetes [7–9]. However, one limitation identified when
using the MAT in international settings for diabetes
management was that it needed further modification to
embrace other internationally recognised guidelines that
heterogeneous healthcare providers might recognise and
access.
The Kuwaiti healthcare system provides healthcare
through both a governmental sector and a private sector.
Primary care is delivered through 80 healthcare centres,
spread amongst 5 healthcare regions, a total of 51 diabetes
clinics existed in primary care centres. Secondary care is
provided through 6 general hospitals, and tertiary care is
provided through 15 specialised centres. There are 5 gen-
eral hospitals in Kuwait which provide outpatient diabetes
care. In addition to graduates from Kuwait University, the
doctors, nurses, and pharmacists in Kuwait have different
educational backgrounds, with training from countries such
as USA, UK, India, Egypt, and other Middle Eastern
countries.
In Kuwait, the latest diabetes guidelines were produced
in 2001, with no regular updates. There is no published
data on prescribing practices for patients with diabetes.
This information is needed as part of a quality assurance
framework aimed at ensuring optimal patient care.
Aim of the study
The present study was designed to evaluate the adherence
to clinical guidelines for treating patients with type 2 dia-
betes mellitus in primary care centres and secondary care
centres (hospitals) using a developed and validated medi-
cation assessment tool (MATKW) derived from interna-
tionally recognised diabetes guidelines.
Methods
Study design
This is a quantitative, cross-sectional study designed to
evaluate the quality of prescribing at primary and second-
ary care settings of patients with type 2 diabetes in Kuwait.
It was conducted between January and June 2010. The
Medical Research Ethics Committee of the Ministry of
Health and the Human Ethical Committee, Health Sciences
Centre, Kuwait University approved the study protocol.
Inclusion criteria and exclusion criteria
Patients included in this study were those who had been
diagnosed with type 2 diabetes mellitus and had started
treatment at least 6 months prior to the study period, cur-
rently alive and had attended the clinics during the past
2 years prior to the study period. Patients with type 1
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diabetes mellitus and those who had not attended the clinic
within the last 2 years prior to the study period were
excluded from the study sample. In addition, patients
C75 years old were excluded as more conservative goals
are often used for this population.
Study sample
The sample size was determined using Java Applets for
Power and Sample Size [10]. It was calculated that a sample
size of 650 patients would be required to determine a 10 %
difference in proportions between two groups (primary and
secondary care facilities) with a 90 % power and a 5 %
significance level. Four secondary care centres out of the five
in Kuwait that provide outpatient diabetes clinics were
selected to be included in the study. In each centre, 80
patients’ medical records were collected using systematic
sampling. The 51 primary care centres that provide diabetes
clinics were stratified according to healthcare regions and
systematic random sampling was used to select a total of 8
primary care centres across four healthcare regions (2 centres
from each region). A total of 332 patients’ medical records
were collected using systematic random sampling.
Development and validation of MATKW
A variety of guidelines are used to treat patients with
diabetes due to the heterogeneous nature of physicians in
Kuwait. This led to the decision to undertake an iterative
process that involved updating and modifying standards in
previous studies conducted in the UK. The recommenda-
tions from the American Diabetes Associations’ standard
of medical care, the European Association for the study of
diabetes, Scottish Intercollegiate Guidelines Network
guidelines and the National Institute for Health and Clini-
cal Excellence (NICE) guidelines were used to develop the
MATKW [2, 11–13]. A total of 55 criteria were developed
from these guidelines. Each criterion is composed of 2
segments: a qualifying statement and a standard. The
qualifying statement would initially be viewed in order to
identify those patients eligible for application of the stan-
dard. Application of the standard on eligible patients
involves choosing an answer category from 5 different
possible answers: Yes—standard is met; No (J)—standard
is not adhered to but an explicitly justified reason is present
and documented in the patient’s notes; No (U)—standard is
not adhered to and there is no explicitly apparent or doc-
umented reason in the patient’s notes; IDQ—insufficient
data on part of the qualifier; IDS—insufficient data on part
of the standard. If a patient is not eligible for application of
the standard, N/A is recorded.
Content validity was established by means of an email
survey to an expert group of 7 consultant endocrinologists (5
from secondary care, 2 from primary care) in Kuwait. The
expert group decided whether they strongly agreed/agreed/
neutral/disagreed/or strongly disagreed with each criterion.
Criteria were eliminated if they were into either ‘disagree’ or
‘strongly disagree’ fields. Face validity was established by
means of a peer review by the research group before field-
testing. The MATKW was pre-tested on a sample of 20
patients’ medical records in a primary care centre. Following
the validation and a further peer review after field-testing, the
final MATKW was produced with 43 criteria that were con-
veniently included into five subheadings.
Data collection and statistical analysis
Data were collected from the selected patients’ medical
records retrospectively from each health facility. Descriptive
and comparative data analysis was performed using SPSS,
version 17 (SPSS Inc., Chicago, IL., USA). Adherence to
every single criterion was calculated as well as the MAT
score, which is the total percentage adherence. This was
calculated from the summation of the total number of cases
where the standard is adhered to (Yes answers) over the
summation of the total number of applicable cases, where the
standard should be adhered to (i.e., Yes, No(U) and IDS
answers). The criteria adherence was judged using arbitrary
cut-offs based on a previous study of similar design (high,
C80 %; intermediate, 50 to\80 %; low\50 %) [14]. The
comparison of data between primary and secondary care
facilities was carried out using Chi square and Mann–
Whitney test. p \ 0.05 was considered to be statistically
significant.
Results
Table 1 shows the patients’ characteristics among the pri-
mary and secondary care facilities included in the study.
The overall results showed that the mean (SD) age was
56.2 (9.6) years, the mean BMI (SD) was 33.6 (6.8) kg/m2,
the mean HbA1c (SD) was 8.5 (1.8) %. There were no
significant differences between patients attending primary
and secondary healthcare facilities in relation to age, BMI
and HbA1c (p [ 0.05). Three hundred and sixty-nine
(56.6 %) were females. Oral antidiabetic therapy alone was
used by 374 (57.4 %), insulin therapy alone by 7 (1.1 %),
and 271 (41.6 %) used both types of medications.
In the overall study sample, only 59.2 % of patients had
their BMI recorded, of which 67.1 % had a BMI C30 kg/m2.
However, 75.0 % of the entire study sample had their HbA1c
recorded, with only 19.2 % of patients reaching the target of
HbA1c \7 %. Target blood pressure (BP) was achieved in
46.0 % of patients in general, while only 38.7 % of patients
with diabetes complications reached their target BP.
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The documentation of patients’ records was variable
when comparing primary and secondary care. In primary
care, BMI and HbA1c were recorded in 68.7 and 62.3 % of
cases, respectively, while in secondary care 49.4 % for
BMI and 88.1 % for HbA1c. Annual visits were recorded in
65.8 % of cases for foot examinations, 64.7 % for eye
examinations and 79.0 % for BP measurements in primary
care; however in secondary care, they were recorded in
78.0 % for foot examinations, 78.2 % for eye examinations
and 98.3 % for BP measurements.
Target HbA1c (\7 %) was achieved in 21.7 % of patients
in primary care compared to only 15.4 % in secondary care.
BMI C30 kg/m2 was found in 68.4 % of patients in primary
care compared to 82.4 % in secondary care. Target BP was
achieved in 52.4 % of patients in primary care compared to
only 38.9 % in secondary care. Target BP in patients with
diabetes complications was achieved in 60.0 % of patients in
primary care compared to 45.1 % in secondary care.
The level of overall adherence was judged as interme-
diate adherence (77.7 %, 95 % CI: 76.7–78.6 %). There
was very low applicability (less than 10 patients) in criteria
6, 7, 13, 14, 17, 27, 38, 39 and 40; and criterion 26 was not
applicable to any patients. Significantly higher total
adherence was found in the secondary healthcare facilities
82.4 % (95 % CI 81.2–83.6 %) compared to primary care
72.5 % (95 % CI 71.0–73.9 %) (p \ 0.001). Moreover, 19
criteria achieved a high adherence ([80 %) in secondary
care compared to 10 in primary care (Table 2).
Out of the 28,036 criteria, only 16,136 relevant criteria
were investigated among the study population, 7,563
(46.9 %) of which were found to be applicable. There were
991 cases of insufficient data (ID), of which 787 (79.4 %)
were considered as IDQ and 204 (20.6 %) were IDS.
Overall non-adherence [(No(J) ? No(U)] was observed in
1,483 (19.6 %), of which 134 (1.8 %) cases were justified.
Table 3 shows the non-adherence to criteria (both justified
and non-justified) at primary and secondary healthcare
facilities.
Discussion
To the best of our knowledge, this is the first study to be
performed in Kuwait using a criterion-based approach with
reference to international treatment guidelines to evaluate
the adherence to international guidelines for treating
patients with type 2 diabetes mellitus at healthcare settings.
The developed and validated MATKW would be a useful
instrument in routine practice as part of clinical audits for
giving feedback to the diabetes care team and identifying
specific care issues that need to be addressed in the absence
of intrinsic locally generated guidelines. It may also be used
as an outcome measure in future intervention studies. The
main findings of this study were an intermediate overall
adherence (77.7 %) to international diabetes guidelines and
inadequate documentation of patients’ records.
The results showed that there were no significant dif-
ferences between patients attending primary and secondary
health care facilities in relation to their age, BMI and
HbA1c. Little is known about the proportion of patients
with diabetes being cared for in primary or secondary care
settings. In general, people with complications or co-mor-
bidities are seen by more specialised doctors at the sec-
ondary care settings, while those in need of general care
and less complicated cases attend primary care. These
findings showed a greater tendency for those patients who
were insulin dependent to be visiting secondary care
(52.8 %) compared to primary care (32.8 %). With the
dramatic increase in prevalence of patients with diabetes,
the Ministry of Health is working towards increasing dia-
betes care services in primary care. A study conducted in
the UK showed that a major barrier to comprehensive and
systematic diabetes care in primary care is lack of ‘‘orga-
nisation’’ [15]. Nowadays, countries worldwide are more
inclined to shift care from secondary care to primary care,
as secondary and tertiary care are more likely to be dis-
organised, discontinuous, uncoordinated and costly, while
development of highly organized systems of primary care
have proven to have lower health care costs.
This study revealed incomplete documentation of
patients’ records at both primary and secondary care set-
tings. In order to ensure optimum continuity of care
between health institutions and personnel, attention to
Table 1 Patients’ characteristics at primary and secondary healthcare








332 (50.9 %) 320 (49.1 %)
Gender 0.43
Male n (%) 139 (41.9 %) 144 (45.0 %)
Female n (%) 193 (58.1 %) 176 (55.0 %)
Age (Years) 0.21
Mean (SD) 56.6 (9.3) 55.7 (9.8)
BMI (kg/m2)a 0.98
Mean (SD) 33.5 (6.4) 33.7 (7.4)
HbA1c (%)
b 0.99
Mean (SD) 8.6 (1.9) 8.5 (1.8)
a 228 Patients at primary care and 158 patients at secondary care,
total of 386 patients
b 207 Patients at primary care and 282 patients at secondary care,
total of 489 patients
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Table 2 Adherence to the audit tool criteria at primary and secondary healthcare facilities
Criterion no. Descriptor % Adherence (95 % CI)
Primary care Secondary care
Secondary prevention of CHD, Stable angina and Post-MI Criteria
1 Use of aspirin in secondary prevention 66.7 (44.9, 88.4) 90.9 (83.3, 98.5)
2 Appropriate dose of aspirin 85.7 (67.4, 100.0) 100 (100.0, 100.0)
3 Use of statin in secondary prevention 66.7 (44.9, 88.4) 96.4 (91.4, 100.0)
4 Use of ACE inhibitor in secondary prevention 55.6 (32.6, 78.5) 81.8 (71.6, 92.0)
5 Use of sublingual glyceryl trinitrate (GTN) 22.2 (3.0, 41.4) 20.0 (9.4, 30.6)
8 Correct timing of oral nitrate dose in patients with stable angina – 92.9 (79.4, 100.0)
9 Use of third line anti-anginals – 100 (100.0, 100.0)
10 Use of ACE inhibitors post-myocardial infarction (MI) 45.5 (16.0, 74.9) 87.2 (76.7, 97.7)
11 Use of beta blockers post-MI 45.5 (16.0, 74.9) 84.6 (73.3, 95.9)
12 Achievement of ACE inhibitor target dose in normal left ventricular function – 59.4 (42.4, 76.4)
Primary prevention
15 Use of aspirin in primary prevention 66.9 (61.5, 72.2) 77.3 (72.1, 82.5)
16 Safe use of aspirin (BP \ 145/90 mmHg) 79.9 (74.0, 85.8) 76.9 (70.3, 83.5)
18 Use of statin in primary prevention 56.4 (50.3, 62.5) 89.5 (85.6, 93.3)
19 Use of statin if LDL [ 2.6 mmol/L 79.6 (73.7, 85.4) 97.8 (95.9, 99.7)
Diabetes-control specific criteria
20 Use of metformin in overweight patient 90.6 (87.4, 93.9) 86.3 (82.4, 90.1)
21 Safe use of metformin 62.2 (56.5, 67.8) 91.7 (88.3, 95.0)
22 Safe use of thiazolidinedione – 95.5 (86.8, 100.0)
Hypertension specific criteria
23 Use of antihypertensive therapy 93.1 (89.3, 96.9) 99.0 (97.6, 100.0)
24 Achievement of target BP 52.4 (44.8, 60.1) 38.9 (32.1, 45.7)
25 Use of ACE inhibitor/Angiotensin-receptor blockers (ARB) for hypertension 82.9 (77.3, 88.6) 91.8 (87.9, 95.6)
27 Safe use of thiazide diuretic 47.8 (33.4, 62.3) –
28 No co-prescribing of thiazide and beta-blocker 89.1 (84.8, 93.4) 99.5 (98.5, 100.0)
29 Plan to exclude drugs that elevate BP 90.2 (85.6, 94.8) 94.4 (91.1, 97.6)
Management of diabetes complications
30 Annual BP measurement 79.0 (71.9, 86.2) 98.3 (96.1, 100.0)
31 Use of anti-hypertensive therapy in presence of complications 83.3 (66.1, 100.0) 97.3 (93.5, 100.0)
32 Achievement of target BP in presence of complications 60.0 (35.2, 84.8) 45.1 (33.5, 56.6)
33 Use of ACE inhibitors in patients with microalbuminuria 64.0 (50.7, 77.3) 52.6 (42.6, 62.5)
34 Use of ARB in patients with microalbuminuria as ACE inhibitor substitute 45.0 (23.1, 66.8) 88.8 (79.7, 98.1)
35 Annual eye screen 64.7 (59.1, 70.2) 78.2 (73.6, 82.8)
36 Annual foot screen 65.8 (60.3, 71.4) 78.0 (73.4, 82.5)
37 Use of tricyclic antidepressants, gabapentin or duloxetine for neuropathy – 62.5 (38.8, 86.2)
Miscellaneous criteria
38 Use of ACE inhibitors in left ventricular systolic dysfunction (LVSD) 8.3 (73.4, 97.2) –
39 Use of ARB as ACE inhibitor substitute in LVSD 58.1 (40.7, 75.4) –
40 Use of clopidogrel as substitute to aspirin 96.6 (89.9, 100.0) –
41 Advice on smoking cessation 45.5 (32.3, 58.6) 24.0 (7.3, 40.7)
42 Use of fibrate if triglyceride levels [ 4.5 mmol/L 81.1 (68.5, 93.7) –
43 Use of fibrate if on statin and triglyceride levels 2.3–4.5 mmol/L 58.6 (40.7, 76.5) 39.1 (19.2, 59.1)
Total adherence (%) (95 % CI) 72.5 (71.0, 73.9) 82.4 (81.2, 83.6)
p value \0.0001
Only criteria with applicability greater than 9 patients are included in the table
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adequate documentation should be encouraged. All primary
care centres in Kuwait have computerised patient medical
records which are very user-friendly but, unfortunately, un-
derutilised. Physicians tend to leave many data fields blank,
maybe out of habit or due to the heavy workload and time
restraints. On the other hand, secondary care settings only
use paper medical records. The introduction and promotion
of information technology in healthcare management has
shown great improvements in patient safety, quality of care
and adherence to evidence-based practice [16]. However,
despite these improvements, practices and physicians varied
greatly in how extensively they used electronic medical
records. It has been shown that one potential solution to the
adoption of electronic medical records is by providing
practice support as well as financial incentives for quality
improvement [16]. In Kuwait, there is a need for methods to
encourage clinicians’ use and adoption of electronic medical
records, and audits to be undertaken to measure any quality
improvement pre- and post-implementation of electronic
medical records systems.
One major contributing factor to the intermediate
overall adherence to prescribing diabetes guidelines iden-
tified by this study could be due to the lack of up-to-date
national guidelines. Furthermore, no other members of the
healthcare team takes part in decision making, which make
the guidelines more difficult to adapt into practice. Com-
mon reasons for this are a process which is non-partici-
patory and/or not widely consultative, which results in a
product to which most of the target group do not feel a
sense of ownership. In addition, a process of implementa-
tion needs to be harmonised with that of distributing the
clinical guidelines to improve engagement by health
workers and use of the new material, changing their
habitual practices [17, 18]. In, Kuwait, diabetes treatment
guidelines need to be regularly updated and appropriately
implemented to maintain authority.
Total adherence was found to be significantly higher in
the secondary healthcare facilities (82.4 %) compared to
primary care (72.5 %). This could be attributed to physi-
cians in hospitals being equipped with more research and/
or clinical-based training in diabetes, while those in
primary care are specialised in ‘‘family medicine’’ and
rarely have specialised qualifications in diabetes and/or
interest in diabetes. A study conducted in the UK showed
that of all the doctor related factors (personality, knowl-
edge, consultation style), only a special interest in diabetes
was shown to be significantly associated with better dia-
betes control [19].
This study was not primarily designed to study the
outcomes of treatment, but it strongly indicates non-opti-
mal achievement of target goals for HbA1c, BP, and BMI
among the study population. It is recommended that the
therapeutic goals for patients with diabetes to reduce the
increased risk of cardiovascular events include achieving
HbA1c \7 %, BP \130/80 mm Hg, LDL-cholesterol \2.6
and 1.8 mmol/L for those at very high risk [2]. Inappro-
priate prescribing practices, poor patient adherence to
medication, unawareness of the importance of therapeutic
goal attainment, and lack of knowledge with regard to
therapeutic goals have been recognised as limitations to
patients achieving these goals [20].
In Kuwait, diabetes care is mainly provided by the
physicians, a potential intervention should be the integra-
tion of an effective multi-disciplinary team approach
including physicians, pharmacists, nurses, and dieticians to
encourage patient education and self-care, and share
responsibility for patients achieving diabetes therapeutic
goal [2]. In Kuwait, there has been little discussion about
the potential role of the pharmacist in the multi-disciplinary
team. This highlights the need for recognition of areas for
pharmacists to become involved in this team. Several
studies have acknowledged the importance of the phar-
macist providing counselling, encouraging effective use of
medicines to achieve glycaemic targets, promoting healthy
lifestyles, supporting self-care, carrying out medication
reviews, and managing disease systemically within multi-
professional teams [21–23]. Further qualitative studies to
allow a comprehensive understanding of the factors asso-
ciated with the specific problems identified by this study,
and cost-effective multifaceted interventions are highly
needed to secure the quality of diabetes management in the
healthcare settings of Kuwait.
Limitations
Our study design used nested sampling and our sample size
calculation did not take nested structure into consideration;
a post hoc power analysis was done using PASS software
with our sample size to compare the total adherence
between secondary and primary care using a clustered
design, and we found statistical power of 90 % holds as
long as the intra class correlation (ICC) is less than 0.3. Our
Table 3 Non-adherence to the audit tool criteria at primary and
secondary healthcare facilities
Primary care Secondary care
n = 3,569a n = 3,994a
No (Justified) 48 (1.3 %) 86 (2.2 %)
No (Unjustified) 794 (22.2 %) 555 (13.9 %)
Total non-adherence 842 (23.6 %) 641 (16.0 %)
a Number of applicable criteria
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data indicated that ICC is much less 0.3 and therefore we
believe our study is not under powered.
Conclusions
The developed and validated MATKW provides a method
for quality assurance of drug therapy use in clinical settings
and may provide a means of establishing acceptable stan-
dards of prescribing adherence to international guidelines
for diabetes care.
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